pregnancy cv exam during pregnancy - oregon acc · pathophysiology • defective antioxidant...

11
5/30/2012 1 ©2011 MFMER | slide-1 Cardiovascular Disease and the Pregnant Patient June 4, 2012 Martha Grogan, MD, FACC ACC 2012 Portland, Oregon ©2011 MFMER | slide-2 Pregnancy Hematologic Changes Am J Physiol, 1983 Am J Physiol, 1983 0 0 Blood volumes (% control) Blood volumes (% control) 10 10 20 20 30 30 40 40 50 50 10 10 20 20 30 30 40 40 Gestational age (weeks) Gestational age (weeks) Plasma Plasma Whole blood Whole blood Erythrocytes Erythrocytes ©2011 MFMER | slide-3 Hemodynamic Changes Hemodynamic Changes > 40% blood volume SVR and PVR HR Mild in BP > 40% blood volume SVR and PVR HR Mild in BP 30-50% CO 30-50% CO ©2011 MFMER | slide-4 S4 occasional S4 occasional Systolic murmur 96% Systolic murmur 96% Wide loud split 1 st 88% Wide loud split 1 st 88% MC MC TC TC A2 A2 P2 P2 Diastolic “flow” murmur 18% Diastolic “flow” murmur 18% S3 loud 84% S3 loud 84% CV Exam During Pregnancy CV Exam During Pregnancy ©2011 MFMER | slide-5 CV Exam During Pregnancy CV Exam During Pregnancy Brisk and full carotid upstroke JVP - normal or mildly Displaced and enlarged apex Varicose veins and edema Normal exam can mimic heart disease Not normal S4, loud SM, DM, fixed split S2 Brisk and full carotid upstroke JVP - normal or mildly Displaced and enlarged apex Varicose veins and edema Normal exam can mimic heart disease Not normal S4, loud SM, DM, fixed split S2 ©2011 MFMER | slide-6 Hemodynamic Changes Labor and Delivery Hemodynamic Changes Labor and Delivery CO 60-80% Volume changes Blood volume with uterine contraction Venous return Volume loss during delivery CO 60-80% Volume changes Blood volume with uterine contraction Venous return Volume loss during delivery

Upload: duongtram

Post on 18-Apr-2018

218 views

Category:

Documents


2 download

TRANSCRIPT

5/30/2012

1

©2011 MFMER | slide-1

Cardiovascular Disease and the Pregnant Patient

June 4, 2012Martha Grogan, MD, FACCACC 2012 Portland, Oregon

©2011 MFMER | slide-2

PregnancyHematologic Changes

Am J Physiol, 1983Am J Physiol, 1983

0000

Blood

volumes

(% control)

Blood

volumes

(% control)

1010

2020

3030

4040

5050

1010 2020 3030 4040

Gestational age (weeks)Gestational age (weeks)

PlasmaPlasma

Whole bloodWhole blood

ErythrocytesErythrocytes

©2011 MFMER | slide-3

Hemodynamic ChangesHemodynamic Changes

•> 40% ↑ blood volume

• ↓ SVR and PVR

• ↑ HR

•Mild ↓ in BP

•> 40% ↑ blood volume

• ↓ SVR and PVR

• ↑ HR

•Mild ↓ in BP

30-50%

↑ CO

30-50%

↑ CO

©2011 MFMER | slide-4

S4occasional

S4occasional

Systolic murmur 96%Systolic murmur 96%

Wide

loud split 1st 88%

Wide

loud split 1st 88%

MCMC TCTC A2A2 P2P2

Diastolic“flow”murmur 18%

Diastolic“flow”murmur 18%

S3loud 84%

S3loud 84%

CV Exam During PregnancyCV Exam During Pregnancy

©2011 MFMER | slide-5

CV Exam During PregnancyCV Exam During Pregnancy

• Brisk and full carotid upstroke

• JVP - normal or mildly ↑↑↑↑

• Displaced and enlarged apex

• Varicose veins and edema

• Normal exam can mimic heart disease

• Not normal

S4, loud SM, DM, fixed split S2

• Brisk and full carotid upstroke

• JVP - normal or mildly ↑↑↑↑

• Displaced and enlarged apex

• Varicose veins and edema

• Normal exam can mimic heart disease

• Not normal

S4, loud SM, DM, fixed split S2

©2011 MFMER | slide-6

Hemodynamic ChangesLabor and DeliveryHemodynamic ChangesLabor and Delivery

• CO ↑ 60-80%

• Volume changes

↑ Blood volume with uterine contraction

↑ Venous return

Volume loss during delivery

• CO ↑ 60-80%

• Volume changes

↑ Blood volume with uterine contraction

↑ Venous return

Volume loss during delivery

5/30/2012

2

©2011 MFMER | slide-7

Heart Disease and Pregnancy: Delivery

• Vaginal Delivery: Preferable in most cases

• Facilitate 2nd stage

• C-Section Indications:

• OB reasons

• Early labor still on warfarin

• Severe PH

• Fixed obstructive lesions

• Unstable aorta

©2011 MFMER | slide-8

Pregnancy “Contraindications”

• Severe Pulmonary Hypertension

• Severe obstructive lesions• AS, MS, PS, HCM, Coarct

• Ventricular dysfunction

• Class III or IV HF, EF <40%

• Dilated or unstable aorta

• Marfan with aorta ≥40 – 45 mm

• Severe cyanosis

©2011 MFMER | slide-9

CAREPREG Risk Stratification

Predictors

• CHF, arrhythmia, TIA or CVA

• NYHA > II or cyanosis

• Left Heart ObstructionMVA <2 cm2, AVA < 1.5

LVOT > 30 mmHg

• LV EF < 40%

Number of predictors

Siu SC et al. Prospective Multicenter Study of Pregancy Outcomes in Women with Heart Disease. Circ

2001; 104:515-521.

©2011 MFMER | slide-10

CARPREG Risk IndexPredictors of Cardiac Events

• Prior CHF, TIA, stroke or arrhythmia

• Baseline NYHA class >II or cyanosis

• Left heart obstruction

• MVA <2 cm2, AVA <1.5 cm2

• LVOT gradient >30 mmHg by Echo

• ↓ systemic vent function (EF <40%)

Risk index predicts CV event rate

©2011 MFMER | slide-11

Dilated Cardiomyopathy

What % of Patients will have an Affected Family Member

a. 5%

b. 10%

c. 15%

d. 25%

e. 50%

CP1081586-12

©2011 MFMER | slide-12

Familial Dilated Cardiomyopathy

• Mid 1980s - initial reports-

1-2% of pts with IDCM had familial disease

Echo screening changed thatJ

5/30/2012

3

©2011 MFMER | slide-13

Dilated Cardiomyopathy A heritable form of heart failureMichels, N Engl J Med 1992

Rationale for clinical screening of families

Impetus for human molecular genetics research

Frequency of familial DCM

• 6-8% by history

• 20-25% by echocardiography

• 35-50% by less stringent criteria

(LV dilation with borderline EF)

©2011 MFMER | slide-14

HFSA 2010 Practice GuidelineGenetic Evaluation—Clinical Screening

Clinical screening (includes echo) for cardiomyopathy in asymptomatic first-degree relatives is recommended

• Hypertrophic cardiomyopathy

• Dilated cardiomyopathy

• Arrhythmogenic RV cardiomyopathy

• Left ventricular noncompaction *

• Restrictive cardiomyopathy *

Lindenfeld J., et al, J Card Fail; 16e1-e194

* Level of evidence = B

©2011 MFMER | slide-15

27-Year-Old FemaleFamilial DCM

©2011 MFMER | slide-16

• Age 15 months

• Pulmonary edema, severely dilated LV, EF 15%

• WPW with SVT

• Index case for family

• Mom and sister: DCM and WPW

• Enrolled in GENES in DCM study (20 yrslater) - actin mutation

27 Year-Old Female – Familial DCM

©2011 MFMER | slide-17

• Competitive soccer – high school and college

• Age 22: inderal changed to coreg, continue dig, ACE-I

• MRI EF 47%, MUGA 44%, Echo 30-35 (est), 40% (calc)

27 Year-Old Female – Familial DCM

©2011 MFMER | slide-18

• Exercise test

• 10.2 min (87%)

• VO2 (79%) with plateau

• What do you recommend regarding pregnancy ?

• How high would you estimate her risk ?

27 Year-Old Female – Familial DCM

5/30/2012

4

©2011 MFMER | slide-19

• At 32 weeks pregnant: exercising 60 min, 4x/ per week

• Asymptomatic

• Echo: EF 35%, increase MR to grade ¾

• Premature Labor – uncomplicated delivery- 35 weeks

• Sister (DCM) uncomplicated preganancy-delivered 4 months later

27 Year-Old Female – Familial DCM

Their Mom J.

©2011 MFMER | slide-20

Peripartum Cardiomyopathy

• New diagnosis of HF due to LV dysfunction

• Last trimester → 6 mos postpartum

• Diagnosis of exclusion

• Incidence varies

US 1 in 3200 deliveries (1350/year)

South Africa 1 in 1000

Haiti 1 in 300

Elkayam JACC 2011

©2011 MFMER | slide-21

Peripartum Cardiomyopathy

• Standard HF Rx – O2, diuretic, iv NTG, inotrope

• Bromocriptine - blocks prolactin release

↑ EF in PPCM vs standard therapy, with AC - TE risk

• IV immune globulin – immune modulator

↑ EF in PPCM pt vs standard therapy

• Pentoxifylline – inhibits TNF-alpha production

↑ TNF-alpha in PPCM

• Anticoagulation if EF <35%, or with bromocriptine

• VAD or transplantation

©2011 MFMER | slide-22

Peripartum Cardiomyopathy

Pathophysiology

• Defective antioxidant defense mechanism

prolactin/bromocriptine

• Viral infection

• Autoimmune response

• Genetic susceptibility

©2011 MFMER | slide-23

Peripartum Cardiomyopathy

• Prognosis variable

• Major cause of preg related death in US

• Mortality 6 mos and 2 yr → 10 and 28%

• ↑ mortality with ↓ EF >6 mos postpartum

• ~50% improve in 6 months

• 20 – 40% normalize EF

©2012 MFMER | 3197755-24

ACC Survey: 44 pts with PPCM• Subsequent pregnancy

Gp 1 – 28 pre-preg normal LVEFGp 2 – 16 pre-preg↓ LVEF

• Pregnancies resulted in ↓ in mean LVEF

Gp 1 – 56±7% → 49±10%;Gp 2 – 36±9% → 32±11%

• CHF symptoms Gp 1 = 21%, Gp 2 = 44%

• Mortality rate Gp 1= 0%, Gp 2 = 19% (P=0.06)

• Subsequent preg – ↓ EF, clinical deterioration and death

• Advise against pregnancy – EF <25% at presentationor persistent ↓ EF

Elkayam et al: N Engl J Med, 2001

5/30/2012

5

©2011 MFMER | slide-25

FDA Classification of Drugs During Pregnancy

A Controlled studies show no risk

B No evidence of risk in humans, the chance of fetal harm is remote

C Risk not excluded. Adequate studies lacking. Chance of fetal harm but benefits outweigh risks

D Positive evidence of risk. Studies in humans show fetal risk. Potential benefit in pregnant women may outweigh risk

X Contraindicated

©2012 MFMER | 3197755-26

Cardiac Drugs in Pregnancy

• Most CV drugs cross placenta, secretedin breast milk

• Avoid when possible

• Use drugs with long safety record

• Prescribe lowest dose for shortest duration

• Avoid multi-drug regimens

• No drug is completely safe

©2012 MFMER | 3197755-27

Cardiac Drugs in Pregnancy

ACE Inhibitors – contraindicated in pregnancy

• 30% fetal morbidity with administration after week 14

• Fetal renal tubular dysplasia, neonatal renal failure

• Oligohydramnios, ↓ cranial ossification, IUGR

Cooper et al: N Engl J Med 2006

• 1st trimester ACE ↑ risk of congenital malformations

• ↑ CV and CNS malformations

• AT II blocker – contraindicated

• Safe during lactation

©2011 MFMER | slide-28

Heart Failure Medications - Pregnancy

• ACE-i/ARBs CONTRAINDICATED

• Metoprolol, Carvedilol– Class C, Atenolol D

• Thiazides – class B

• Loop diuretics – class C

Avoid Hypotension, Placental Hypoperfusion

• Nitrates – class C

• Hydralazine – class C

©2011 MFMER | slide-29

Aortic Disease and Pregnancy

©2011 MFMER | slide-30

Pregnancy and Marfan Syndrome

• Preexisting medial changes

• Changes with pregnancy

• Physiologic, hormonal

• Unpredictable maternal risk

• Dissection, rupture, IE, CHF

• Fetal risk

• 50% inheritance

5/30/2012

6

©2011 MFMER | slide-31

Pregnancy and Marfan Syndrome

ESC GUCH Guidelines 2010

• 50% chance inheritance risk → genetic counseling

• Aorta >45 mm - strongly discourage pregnancy, high

risk of dissection

• Aorta <40 mm rare problem; no safe diameter

• Aorta 40-45 mm, aortic growth and FH important

Even after aortic repair, Marfan patients remain at

risk for dissection of residual aorta

©2011 MFMER | slide-32

©2011 MFMER | slide-33

©2011 MFMER | slide-34

©2011 MFMER | slide-35

Valvular Heart Disease and Pregnancy

©2012 MFMER | 3197755-36

Pulmonary Edema

Mitral Stenosis in Pregnancy

↑↑↑↑ HR

↓↓↓↓ diastolic

filling

↓↓↓↓ SV

Reflex ↑↑↑↑ HR

Further ↑ in LA pressure

5/30/2012

7

©2012 MFMER | 3197755-37

Mitral StenosisManagement in Pregnancy

ββββ blockade, maintain NSR

anticoagulation, diuretics

Balloon valvotomy

Surgical valvotomy or MVR

©2012 MFMER | 3197755-38

↓↓↓↓ Placental perfusion

IUGR, preterm labor

Aortic Stenosis in Pregnancy

Unable to

augment CO

Preload and

hypotension

sensitive

CHF and ischemia

©2011 MFMER | slide-39

Anticoagulation in Pregnancy

©2011 MFMER | slide-40

©2011 MFMER | slide-41

©2011 MFMER | slide-42

Complex CHD in Pregnancy

5/30/2012

8

©2011 MFMER | slide-43

21-Year-Old FemaleSingle Ventricle, Fontan

• Transfer from pediatric cardiology – due to ?

• Complete AV canal, mitral and pulm.valve atresia, single ventricle-RV

• Atrial septectomy, classic BT(neonate)

• Fontan, age 11, bidirectional Glenn, lateral tunnel baffle IVC-RPA

©2011 MFMER | slide-44

21-Year-Old FemaleSingle Ventricle, Fontan

• Pre-pregnancy – asymptomatic

• SVT – digoxin

• EF 45-50% -lisinopril

• Exercise test – 8 min (76%)

• VO2- 21.3 (71%)

©2011 MFMER | slide-45

21-Year-Old FemaleFontan, Pregnancy #1

• 28 weeks – palpitations, near syncope

• Rx- heparin

• Fatigue and DOE, 35 wks

• CS – 2485 g

• Post partum – ICU –IV fluids

• Required diuresis

©2011 MFMER | slide-46

22-Year-Old FemaleFontan, 10 months post partum

• Presents - 5 months pregnant!

• Uncomplicated

• Planned CS – 37 weeks

• 2855 g

• No ICU – no fluid overload

©2011 MFMER | slide-47

25-Year-Old FemalePost Fontan, Pregnancy #3

• No care until 5 months

• More SVT – better with inderal

• IUGR (2nd %tile)

• CS at 36 weeks – 2103 g

• No maternal complications

• Baby – VSD – heart failure - surgery

• Vasectomy planned

©2011 MFMER | slide-48

31-Year-Old FemalePost Fontan

•5/2011: Research study

•Guess what?

•“Dr. Grogan will kill me!”

5/30/2012

9

©2011 MFMER | slide-49

Echo 2010

©2011 MFMER | slide-50

Echo 2010

©2011 MFMER | slide-51

Echo 2010

©2011 MFMER | slide-52

Pregnancy after Fontan

Contraindications

•EF <40%

•Class III-IV symptoms

•Cyanosis

•PLE

©2011 MFMER | slide-53

Pregnancy Post Fontan

• Atrial arrhythmias

• Ventricular Dysfunction

• Edema and Ascites

• Challenges of A/C mgmt.

• Spontaneous Abortion

• IUGR and Premature Birth

©2011 MFMER | slide-54

5/30/2012

10

©2011 MFMER | slide-55

Arrhythmias and Pregnancy

©2011 MFMER | slide-56

Arrhythmias and Pregnancy

• Palpitations common – often benign

• SVT most common

• Afib/flutter with CHD

• Hemodynamic instability: DC cardioversion

• Vagal maneuvers, adenosine

• Meds:1st line: Digoxin, metoprolol*

• Antiarrhythmic Rc – reserve for severe symptoms, recurrence

* Avoid atenolol- class D

©2011 MFMER | slide-57

Arrhythmias and Pregnancy

• VT – uncommon

• Antiarrhymic Rx: quinidine, procainamide, flecainide, sotolol

• Amiodarone – seldom used

• Ablation has been safely performed in pregnancy (atrial and ventricular arrhythmia)

• PPM and ICD can be performed

©2011 MFMER | slide-58

Pregnancy: MI, Radiation, Endocarditis

©2012 MFMER | 3197755-59

Acute MI in Pregnancy

• Exclude coronary anomaly and aortic dissection

• Coronary angio, aortic imaging

• PCI – bare metal stent

• CABG – limited data

• Thrombolysis

• Consider if cath/PCI not available

Roth: JACC 2008

©2011 MFMER | slide-60

5/30/2012

11

©2011 MFMER | slide-61

©2011 MFMER | slide-62

Cardiovascular Disease and PregnancySummary

• CVD complicates 1-2 % of pregnancies

• CHD most common in US

• Does not preclude successful outcome

• Increased risk: mother and fetus

• Individualized assessment

Preferably Prior to Conception